



US008765722B2

(12) **United States Patent**
Cho et al.

(10) **Patent No.:** **US 8,765,722 B2**
(45) **Date of Patent:** ***Jul. 1, 2014**

- (54) **INHIBITORS OF FLAVIVIRIDAE VIRUSES**
- (71) Applicant: **Gilead Sciences, Inc.**, Foster City, CA (US)
- (72) Inventors: **Aesop Cho**, Mountain View, CA (US); **Lee S. Chong**, Newark, CA (US); **Michael O'Neil Hanrahan Clarke**, Redwood City, CA (US); **Edward Doerffler**, Union City, CA (US); **Choung U. Kim**, San Carlos, CA (US); **Qi Liu**, Foster City, CA (US); **William J. Watkins**, Saratoga, CA (US); **Jennifer R. Zhang**, Foster City, CA (US)
- (73) Assignee: **Gilead Sciences, Inc.**, Foster City, CA (US)
- (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

2004/0116509	A1	6/2004	Chan Chun Kong et al.
2005/0119332	A1	6/2005	Jeppesen et al.
2006/0142347	A1	6/2006	Chan Chun Kong et al.
2006/0276533	A1	12/2006	Denis et al.
2007/0099929	A1	5/2007	Thede et al.
2008/0299080	A1	12/2008	Chan Chun Kong et al.
2009/0274655	A1	11/2009	Grimes et al.
2011/0020278	A1	1/2011	Canales et al.
2011/0178058	A1	7/2011	Canales et al.
2011/0178129	A1	7/2011	Canales et al.
2013/0052161	A1	2/2013	Watkins et al.

FOREIGN PATENT DOCUMENTS

WO	WO-02/100846	12/2002
WO	WO-02/100851	12/2002
WO	WO-2004452885	A1 6/2004
WO	WO-2005/095386	10/2005
WO	WO-2006/072347	7/2006
WO	WO-2006/072348	7/2006
WO	WO-2007/093365	8/2007
WO	WO-2008/058393	5/2008
WO	WO-2010/065668	6/2010
WO	WO-2011/011303	1/2011
WO	WO-2011/068715	6/2011
WO	WO-2011/088345	7/2011
WO	WO-2012/006055	1/2012

- (21) Appl. No.: **13/927,355**
- (22) Filed: **Jun. 26, 2013**
- (65) **Prior Publication Data**
US 2013/0302280 A1 Nov. 14, 2013

Related U.S. Application Data

- (63) Continuation of application No. 13/392,467, filed as application No. PCT/US2010/047983 on Sep. 7, 2010, now Pat. No. 8,501,714.
- (60) Provisional application No. 61/240,874, filed on Sep. 9, 2009.
- (51) **Int. Cl.**
A61K 31/67 (2006.01)
A61K 31/675 (2006.01)
C07F 9/6558 (2006.01)
C07F 9/6553 (2006.01)

- (52) **U.S. Cl.**
USPC **514/81**; 514/89; 514/92; 514/95; 544/244; 546/22; 548/119; 549/6

- (58) **Field of Classification Search**
USPC 424/85.4; 549/6; 548/119; 544/244; 546/22; 514/95, 92, 81, 89, 43
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,861,421	A	1/1999	Christensen, IV et al.
6,881,741	B2	4/2005	Chan Chun Kong et al.
6,887,877	B2	5/2005	Chan Chun Kong et al.
7,402,608	B2	7/2008	Chan Chun Kong et al.
7,521,473	B2	4/2009	Lee et al.
7,569,600	B2	8/2009	Denis et al.
8,501,714	B2*	8/2013	Cho et al. 514/81
2002/0002199	A1	1/2002	Jeppesen et al.
2003/0229053	A1	12/2003	Chan Chun Kong et al.

- OTHER PUBLICATIONS**
- U.S. Appl. No. 13/801,011, filed Mar. 13, 2013, Watkins et al.
 - U.S. Appl. No. 13/801,039, filed Mar. 13, 2013, Evans et al.
 - U.S. Appl. No. 13/800,991, filed Mar. 13, 2013, Hashash et al.
 - International Search Report and Written Opinion for Application No. PCT/US2011/021279, mailed May 2, 2011.
 - International Search Report and Written Opinion for Application No. PCT/US2011/021335, mailed Feb. 22, 2011.
 - International Search Report and Written Opinion for Application No. PCT/US2010/042394, mailed Sep. 29, 2010.
 - Office Action for U.S. Appl. No. 12/838,684, mailed Aug. 2, 2012.
 - Notice of Allowance for U.S. Appl. No. 13/006,761, mailed Oct. 3, 2012.
 - Office Action for U.S. Appl. No. 13/007,150, mailed Oct. 3, 2012.
 - Boyer, N, et al. (2000) "Pathogenesis, diagnosis and management of hepatitis C," *Journal of Hepatology* 32 (suppl 1):98-112.
 - Calisher, C. et al. (1989) "Antigenic Relationships between Flaviviruses as Determined by Cross-neutralization Tests with Polyclonal Antisera," *J.gen. Virol.* 70:37-43.
 - Di Besceglie, A. et al. (1999) "Some 1.8 percent of the U.S. adult population are infected with the hepatitis C virus, most without knowing it" *Scientific American* October pp. 80-85.

(Continued)

Primary Examiner — Kristin Vajda
(74) *Attorney, Agent, or Firm* — Kilpatrick Townsend & Stockton LLP

(57) **ABSTRACT**

Provided are compounds of Formula I: and pharmaceutically acceptable salts and esters thereof. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections, particularly hepatitis C infections.

27 Claims, No Drawings